Tidal Investments LLC Acquires 43,207 Shares of Medtronic PLC $MDT

Tidal Investments LLC raised its holdings in shares of Medtronic PLC (NYSE:MDT) by 17.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 290,007 shares of the medical technology company’s stock after buying an additional 43,207 shares during the period. Tidal Investments LLC’s holdings in Medtronic were worth $22,687,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Monetary Solutions Ltd purchased a new position in shares of Medtronic during the 4th quarter worth $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 4th quarter worth $29,000. IAG Wealth Partners LLC bought a new position in Medtronic in the 2nd quarter worth $30,000. Imprint Wealth LLC bought a new position in shares of Medtronic in the third quarter worth about $31,000. Finally, Basepoint Wealth LLC bought a new position in shares of Medtronic in the fourth quarter worth about $32,000. 82.06% of the stock is currently owned by institutional investors.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analyst maintains Buy rating: William Blair analyst Brandon Vazquez reaffirmed a Buy rating, citing Medtronic’s strong fiscal 2027 outlook and an attractive risk/reward profile. Analyst Brandon Vazquez Reaffirms Buy on Medtronic
• Positive Sentiment: Cardiovascular growth is accelerating: Medtronic’s heart-device businesses are outperforming the broader med-tech sector, helping drive fiscal 2027 first-quarter revenue of approximately $9.8 billion and 13.7% organic growth. Demand was particularly strong in cardiovascular products. Medtronic’s Heart Devices Are Suddenly Outgrowing the Rest of Med-Tech
• Positive Sentiment: Fiscal 2027 outlook raised: Management increased its organic revenue-growth forecast and raised the lower end of its adjusted earnings outlook after exceeding quarterly expectations. The broad-based growth supports the case for improving business momentum. Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum
• Neutral Sentiment: Income appeal remains notable: Medtronic has increased its dividend for 49 consecutive years and offers a yield near 3%, putting it within two years of potential Dividend King status. This may support demand from income-focused investors, although dividend-related news is unlikely to be a major near-term catalyst. Medtronic Is on the Cusp of Becoming a Dividend King
• Negative Sentiment: Execution risks remain: Analysts and commentators question whether the cardiovascular growth rate can persist, particularly as Medtronic faces margin pressure, competition and the approaching exit from its diabetes business. A reporting period with an extra selling week also makes the headline growth rate somewhat easier to achieve. Medtronic Raised its Outlook as Heart Devices Accelerate

Medtronic Trading Down 0.3%

MDT stock opened at $91.60 on Friday. The firm has a fifty day moving average price of $87.75 and a 200 day moving average price of $85.13. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The firm has a market cap of $117.17 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 2.16 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Medtronic’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.96 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is currently 70.94%.

Analyst Ratings Changes

A number of brokerages recently issued reports on MDT. Robert W. Baird boosted their price objective on Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. Leerink Partners decreased their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Bank of America lifted their price target on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. UBS Group upped their price target on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Finally, Needham & Company LLC increased their price objective on shares of Medtronic from $101.00 to $114.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Nineteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $103.92.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.